Company ProfilePremium

iQ3Corp Ltd

Company Profile Analysis

Ticker: IQ3.AX

ESOMAR 23 Corporate BadgeISO Certifications Badge
iQ3Corp Ltd - Company showcase

Year Founded & Workforce

2012

iQ3Corp Ltd logo

iQ3Corp Ltd Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

iQ3Corp Ltd Overview

FieldDetailSource
Legal nameiQ3Corp Ltd (Administrators Appointed)Federal Court of Australia, [2022] FCA 397 (6 Apr 2022)
Former namesNone recordedMarket Index IQ3 profile
ACN160 238 282FY2020 Annual Report cover; [2022] FCA 397
Incorporation year2,012MarketBeat / Investing.com company profiles (aggregator); consistent with ACN series
Incorporation jurisdictionAustralia (public company limited by shares, Corporations Act 2001 (Cth))FY2020 AR, Note 1
Registered office / HQ (last reported)Level 9, 85 Castlereagh Street, Sydney NSW 2000FY2020 AR, Corporate Directory
Share registryBoardroom Pty Limited, Level 12, 225 George Street, Sydney NSW 2000FY2020 AR
Exchange / tickerASX: IQ3 (listed 18 May 2015; suspended; removed 26 Aug 2022)[2022] FCA 397; ASX Market Announcement 29 Aug 2022
ISINNot publicly disclosed in sources retrieved (AU-prefixed ISIN would have applied)—
CUSIPNot applicable (no US listing)—
Fiscal year end30 JuneFY2020 AR
EmployeesNot publicly disclosed. Proxy: employee benefits expense A$1.76m (FY2020) vs A$2.87m (FY2019)FY2020 AR, Note 7
Auditor (last)Vincents Audit Pty Ltd, Canberra (engagement director Phillip William Miller CA)FY2020 AR, auditor's independence declaration
Regulatory licence statusCorporate authorised representative of AFSL 451144FY2020 AR, Review of operations
Shares on issue (30 Jun 2020)103,925,001 fully paid ordinary sharesFY2020 AR, Note 20
Market capitalisation (current)Not applicable (delisted). Last quoted price A$0.12, implying about A$12.5m on 103.9m shares (historical, illiquid)Investing.com historical data
Market capitalisation at IPOA$30.545m at A$0.30 per shareIPO close announcement, May 2015
Websitehttp://iq3corp.com (as supplied; www.iQ3Corp.com cited in FY2020 AR).FY2020 AR
External administratorsMark Robinson, Riad Tayeh and Antony Resnick (joint and several)[2022] FCA 397

iQ3Corp Ltd was a micro-cap Australian corporate finance boutique that described itself as the world's first dedicated life science corporate finance and advisory firm. It provided capital raising, IPO and listing advisory, M&A, structured finance, restructuring and NSX nominated-adviser services to biotech, medtech and pharmaceutical companies in Australia and, through US subsidiaries, the United States. In practice it was a captive service provider inside the "iQ Group" of companies founded by Dr George Syrmalis. Its FY2020 accounts state that 100% of revenue came from related parties, and the group's administrators later described a web of intercompany loans and shared-labour arrangements. Revenue grew from A$2.1m (FY2016) to A$6.9m (FY2020), but losses widened, equity turned negative and the auditor flagged a going-concern material uncertainty. The group collapsed into voluntary administration in March 2022, and iQ3Corp was delisted from the ASX in August 2022. It is now a distressed-asset and governance case study rather than a going concern.


Company's own description (FY2020 Annual Report)

The FY2020 Directors' Report gives the principal activity as the provision of capital raising and corporate advisory services to listed and unlisted companies in the life science industry. The Review of Operations positions the company as a specialist corporate finance adviser to the life science sector. It describes expertise in mergers and acquisitions, strategic matters, restructuring and capital structure, and capital raising, offered to corporations, partnerships, institutions, governments and individuals. The FY2019 Annual Report called iQ3Corp the world's first dedicated life science corporate finance firm, under the tagline "Translating Science into Capital and Beyond".

In FY2020 management said the company had advised boards and executives on the best business model for commercialising new life science intellectual property. That work covered market entry, funding, licensing and partnering strategies, and identifying counterparties in Australia and offshore. Management also cited new projects and collaborations with US business partners, which it expected to produce a pipeline of work over the following 12–24 months.

Aggregator profiles (MarketBeat, Investing.com) add IPO and listing advisory, private equity, structured finance, sell-side and buy-side mandates, and NSX nominated-adviser services to the list.

Business model and revenue model

Revenue streamModel typeFY2020 (AUD)FY2019 (AUD)Share of FY2020 revenue
Capital raising and corporate advisory feesProfessional services: project/success fees, fixed price or hourly6,760,2115,647,65998.0%
Office and shared services revenueCost-recovery / service fees charged to related entities139,757513,1902.0%
Total—6,899,9686,160,849100%

Source: FY2020 Annual Report, Notes 4 and 5. All revenue was recognised over time as services were rendered, on either a fixed price or an hourly rate (Note 5 accounting policy). There was no product, subscription or licensing revenue. The company did hold "licences" as an indefinite-life intangible asset (A$307,986 at 30 June 2020), but these generated no disclosed revenue.

Independent characterisation

On paper, iQ3Corp was an advisory boutique. Economically, it functioned as a related-party service vehicle. Three disclosures from FY2020 are decisive:

  1. Customer concentration of 100% to related parties. Note 4 states that the Group's revenue came only from related parties. Note 30 confirms that all A$6.76m of advisory fees and all A$0.14m of shared-services fees were received from related parties. The related entities were The iQ Group Global Ltd (formerly iQnovate), iQX Limited, OncoTEX entities, Biosensx (North America) Pty Ltd and New Frontier Holdings LLC.

  2. Cash conversion was weak. Related-party receivables were A$2.48m gross at 30 June 2020, against FY2020 revenue of A$6.90m, or roughly 126 days of revenue.

  3. Funding came from inside the group. Liquidity relied on a A$927,000 bond from related party iQX (9% coupon, maturing 30 June 2022) and an undrawn A$3m iQX working capital facility, also at 9%. The going-concern basis rested on related-party capital-raising fees and related-party funding.

The auditor's key audit matters were going concern, related party transactions, and recognition and impairment of intangibles. The audit report described a group of subsidiaries and companies with varying ownership levels, which transacted with one another and performed similar functions in different market sectors.

The administrators' evidence to the Federal Court in April 2022 confirmed this picture. Entities in the iQ Group relied on each other for day-to-day funding. There were many intercompany loans, often written off or reclassified without adequate explanation, and loan balances were inconsistent between counterparties. Entities sometimes paid other entities' employees, and shared-labour arrangements were common. The administrators considered Farmaforce, not iQ3Corp, to be the group's principal operating company ([2022] FCA 397, paras 4–5).

Value chain position

Value-chain stageActivityiQ3Corp role
Discovery / IP originationUniversity and research-institute IP, early-stage biotechNone directly; sourced via sister company iQ Group Global (IP asset manager)
Corporatisation and structuringCompany formation, IP licensing, structuringAdvisory (stated FY2020 focus: "finding, funding, corporatising and capitalising early stage biotech assets", per Lei Xu biography)
Capital raisingSeed, pre-IPO, IPO, secondary raisingsCore fee-earning service
Listing / nominated adviserASX and NSX listings; NSX nominated adviserService offered (NSX nominated adviser per aggregator profiles)
Investment / funds managementBioscience fundsSister company iQX Limited (NSX: IQX)
Commercial executionPharma sales forces, medical affairsSister company Farmaforce Ltd (ASX: FFC)

iQ3Corp sat between life science asset originators and capital markets:

Customer types and end-markets

Customer typeEvidenceNotes
Related-party life science companiesFY2020 AR Note 30: 100% of revenueiQ Group Global, iQX, OncoTEX, Biosensx, New Frontier
Listed and unlisted biotech/medtechStated target marketNo disclosed third-party clients in FY2020
Governments, institutions, individualsStated in boilerplateNo disclosed revenue
US life science companiesUS subsidiaries (iQ Capital (USA) LLC etc.)Revenue geographically disclosed as Australia only

End-markets: biotechnology, medical devices and diagnostics (notably saliva-based biosensors developed within the wider iQ Group), oncology (OncoTEX associate) and pharmaceutical services.

Strategy

Stated strategy (FY2019–FY2020 Annual Reports)

The main strategic themes in the last two annual reports were:

  1. Distribution build-out across Australia and the USA, raising the group's profile in the life science industry and positioning it in capital markets (FY2019 and FY2020 Chair's Reports).

  2. US expansion through new projects and collaborations with US business partners and investment banking via iQ Capital (USA) LLC. Management said several significant contracts had been signed, giving a pipeline for the next 12–24 months (FY2020).

  3. IP commercialisation advisory, including acquiring and licensing life science assets for new and existing clients, which management expected to generate more corporate advisory work (FY2020).

  4. Mission statement (FY2020 Chair): to make a difference in the Australian life science sector by giving it access to capital markets and the opportunity to become a major global force.

Initiatives register (last 24 months of disclosure, FY2019–FY2021)

DateInitiativeDetailOutcome
FY2020Cost-saving programmeOperational review produced positive Q4 FY2020 operating cash flow of A$203k. "Full impact" expected in FY2021Full-year FY2020 operating cash flow still −A$862k
31 Dec 2019Related-party bondA$927k from iQX at 9%Drawn; maturity 30 Jun 2022 fell after administration
30 Apr 2020"Strategic partnership" / liquidity facilityA$3m iQX working capital facility at 9%, maturing 30 Jun 2022Undrawn at 30 Jun 2020; iQX entered administration in Mar 2022
FY2020US business partnershipsUnnamed US partners; "several significant contracts"No US revenue recognised in FY2020
FY2019–FY2020Associate investmentsFurther investment in New Frontier Holdings LLC (A$74,942 in FY2020; A$82,800 in FY2019)Equity-accounted; OncoTEX valuation later treated as confidential in court ([2022] FCA 397)
FY2020Board restructuringExecutive Chair model adoptedIndependence removed

ESG and sustainability commitments

None disclosed. The Directors' Report stated that operations were not subject to significant environmental regulation.

Medium-term targets and guidance

Not publicly disclosed. The company never published quantitative revenue, margin or return targets.

Products & Services

iQ3Corp did not publish a priced service catalogue. The services below are drawn from the FY2019 and FY2020 annual reports and aggregator profiles derived from company disclosures. Pricing was disclosed only at policy level: fixed price or hourly rate, recognised over time.

Consulting Services segment

ServiceDescriptionTarget customerPricing modelEvidence
Capital raisingArranging equity capital for listed and unlisted life science companiesEarly-stage and listed biotech/medtechFees (fixed/hourly; success fees not separately disclosed)FY2020 AR principal activities
IPO and listing advisoryPreparing companies for ASX/NSX listingPre-IPO life science companies—MarketBeat/Investing.com profiles
NSX nominated adviser servicesActing as nominated adviser for NSX-listed issuersNSX issuers (including related parties)—Aggregator profiles
Mergers and acquisitionsSell-side and buy-side advisoryLife science corporates—FY2020 AR; aggregator profiles
Private equity advisoryPrivate capital transactionsLife science companies—Aggregator profiles
Structured finance / structured investment productsStructured funding solutions——Aggregator profiles; Lei Xu former title
Restructuring and capital structureBalance sheet and capital structure adviceDistressed/transitional companies—FY2020 AR
Strategic and commercialisation advisoryBusiness model, market entry, licensing and partnering strategy for new life science IPBoards and executives of IP-owning companies—FY2020 AR Review of operations
Asset corporatisation"Finding, funding, corporatising and capitalising early stage biotech assets"Early-stage biotech assets—FY2020 AR (Lei Xu biography)
US investment banking (via iQ Capital (USA) LLC)US capital-markets activityUS life science companies—FY2020 AR going-concern note

Shared Services segment

ServiceDescriptionCustomerFY2020 revenue (AUD)
Office sharing and shared servicesOffice space and administrative services recharged to related entitiesiQ Group companies139,757

Note that iQ3Corp was also a net buyer of shared services. It paid A$1,614,105 in office-sharing costs to related parties in FY2020 (FY2019: A$1,028,541), more than ten times what it earned from shared services.

Equity interests that functioned as "portfolio products"

HoldingNatureCarrying value 30 Jun 2020 (AUD)
New Frontier Holdings LLC (40%) and OncoTEX Holdings Inc (40.5%)Equity-accounted associates581,206 (combined line)
Shares in a listed company (unnamed)FVOCI financial asset, Level 170,126
LicencesIndefinite-life intangible307,986

Financial Narrative

Coverage: FY2016–FY2020 audited (FY2020 Annual Report 5-year table plus full FY2019/FY2020 statements).

Income statement (chartable)

Derivations: EBIT = loss before tax + finance costs − interest revenue. FY2020: −2,212,596 + 157,853 − 61 = −2,054,804. FY2019: −1,098,530 + 64,842 − 12 = −1,033,700. EBITDA adds depreciation (FY2020 A$25,568; FY2019 A$35,317). There was no amortisation. Income tax expense was nil in both years. Sources: FY2020 AR statement of profit or loss, Note 7 and the remuneration report's 5-year table. FY2018 EPS is reported as nil.

Margins (chartable)

Revenue CAGR: FY2016–FY2020 (4 years) 34.4%; FY2017–FY2020 (3 years) 5.5%; FY2018–FY2020 (2 years) 3.3%.

Commentary. The revenue series has two phases. FY2016–FY2017 shows a steep ramp from a small base (+177.5%) as the newly listed company built up related-party mandates. FY2017–FY2020 shows a plateau between A$5.9m and A$6.9m. The best year for profitability was FY2018, which was near breakeven. Profitability then deteriorated even as revenue rose in FY2020. Gross profit fell 31% to A$2.95m while revenue rose 12%, because cost of sales more than doubled from A$1.87m to A$3.95m. Management attributed this to higher employee-related costs within cost of sales, incurred to build the infrastructure needed for its strategy. Office-sharing costs paid to related parties rose 57% to A$1.61m, and consultancy fees nearly quadrupled from A$0.25m to A$0.94m.

Revenue therefore grew without operating leverage. Because both revenue (fees from related parties) and a large share of costs (office-sharing charges paid to related parties) were set within the group, reported margins say more about intragroup pricing than about any market-tested advisory economics. The FY2020 figure also includes A$191k of COVID-19 government support in other income. Without it, the loss would have been about A$2.40m.

Operating expense detail (FY2019–FY2020)

Source: FY2020 AR statement of profit or loss and Note 7.

Balance sheet (chartable)

FY2018 figures are opening balances from the FY2020 statements of cash flows and changes in equity. Total debt at 30 June 2020 is the iQX related-party bond (A$927,000 principal plus A$42,559 accrued interest), classified as non-current with maturity on 30 June 2022. Source: FY2020 AR statement of financial position and Notes 9, 10, 18 and 20.

Commentary. The balance sheet shows rapid capital erosion. Equity fell from A$1.90m (30 June 2018) to A$0.89m (30 June 2019) and then to a deficiency of A$0.99m (30 June 2020), with no new equity raised after the IPO (contributed equity unchanged at A$7.18m). Related-party receivables made up 68% of total assets, so the asset base largely consisted of claims on sister companies that later went into administration themselves. In the administration, those receivables would have been recoverable only as unsecured claims against insolvent estates. The administrators said that, in a liquidation, unsecured creditors of the group entities were unlikely to receive any distribution. Net current liabilities widened from A$0.13m to A$0.96m. Sundry payables and accrued expenses rose from A$0.99m to A$2.35m, which suggests the company was stretching payments to creditors.

Cash flow (chartable)

Source: FY2020 AR statement of cash flows. Management reported positive operating cash flow of A$203k in Q4 FY2020 after cost-saving initiatives, a quarterly figure not separately audited. The full-year A$862k operating outflow was funded almost exactly by the A$927k related-party bond.

Ratios (chartable)

Notes: FY2020 ROE and debt to equity are not meaningful because equity was negative. ROIC is not meaningful (negative NOPAT, negative equity). Net debt to EBITDA is not meaningful because EBITDA was negative. Interest coverage uses interest expense (FY2020 A$144,132; FY2019 A$55,016). A full cash conversion cycle is not meaningful for a services firm with no inventory, so DSO is shown instead.

Synthesis of trends. The data shows (1) revenue stalling at about A$6–7m after FY2017; (2) a structural rise in costs from FY2019, partly charged by related parties; (3) negative and worsening cash generation; (4) equity eliminated within two years; and (5) a growing reliance on related-party debt. The going-concern material uncertainty in FY2020 was the formal warning of the March 2022 collapse.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Segment Overview

SegmentContentsProducts/servicesCustomers

Consulting services

Capital raising and corporate advisory fees

IPO/listing advisory, capital raising, M&A, structured finance, restructuring, strategic advisory, commercialisation advisory

Related parties only (FY2020)

Shared services

Office and shared services revenue

Office space, administration and shared services recharged to group companies

Related parties only

Revenue by Segment

SegmentFY2019FY2020

Consulting services revenue (AUD K)

5,6486,760

Shared services revenue (AUD K)

513140

Total revenue (AUD K)

6,1616,900

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Revenue by Segment (%) and Segment Margins & Growth (%)

Segment metricFY2019FY2020

Consulting services share of revenue (%)

91.798.0

Shared services share of revenue (%)

8.32.0

Consulting services YoY growth (%)

—19.7

Shared services YoY growth (%)

—-72.8

Group Entities

EntityJurisdictionOwnershipRole (inferred where not stated)

iQ3Corp Limited

Australia

Parent

Listed holding and advisory company

iQ Group (Global) LLC

USA

100%

US holding/operations

The Biotech Company Pty Ltd

Australia

100%—

Sonholdings LLC (trading as Son Enterprise in NY)

USA

100%

New York operations

iQ Capital (USA) LLC

USA

100%

US investment banking (cited in going-concern note as a source of future funds)

The iQ Capital (Operations) LLC

USA

100%

US operations

Capital Labs Pty Ltd

Australia

100%—

New Frontier Holdings LLC

USA

40% associate

Holds Nereid Enterprises Pty Ltd (Aus) and Nereid Enterprises LLC (USA)

OncoTEX Holdings Inc

USA

40.5% associate

Holds OncoTEX Inc (USA) and OncoTEX Pty Ltd (Aus); oncology venture

“—” = not publicly disclosed.

Group Entities — The iQ Group Global Ltd

EntityListingFunction (per administrators' evidence)

The iQ Group Global Ltd (formerly iQnovate)

NSX, 15 Dec 2011 – delisted 19 Sep 2022

Asset manager of scientific IP; finds, funds and develops bioscience discoveries

iQX Limited

NSX, 10 Dec 2013 – delisted 19 Sep 2022

Bioscience investment funds manager; iQ3Corp's lender

Farmaforce Limited

ASX, 27 Oct 2015 – delisted 26 Aug 2022 (as A.C.N. 167 748 843 Limited)

Contract pharmaceutical sales force; principal operating company

iQ3Corp Ltd

ASX, 18 May 2015 – delisted 26 Aug 2022

Life science corporate finance advisory

Income Statement and Margin Analysis (%)

MetricFY2016FY2017FY2018FY2019FY2020

Revenue (AUD K)

2,1185,8756,4626,1616,900

Revenue YoY growth (%)

—177.510.0-4.712.0

Gross profit (AUD K, FY2019 restated)

———4,2932,946

EBIT / operating result (AUD K, derived)

———-1,034-2,055

EBITDA (AUD K, derived)

———-998-2,029

Pre-tax income (AUD K)

———-1,099-2,213

Net income (AUD K)

-1,988-50-1-1,099-2,213

EPS basic (AUD cents)

-1.95-0.050-1.06-2.13

EPS diluted (AUD cents)

-1.95-0.050-1.06-2.13

Dividends per share (AUD cents)

00000

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Margin

MarginFY2016FY2017FY2018FY2019FY2020

Gross margin (%)

———69.742.7

EBIT margin (%)

———-16.8-29.8

EBITDA margin (%)

———-16.2-29.4

Net margin (%)

-93.9-0.80.0-17.8-32.1

Expense line

Expense lineFY2019FY2020

Cost of sales (AUD K, FY2019 restated)

1,8673,954

Employee benefits expense (AUD K, restated)

2,8711,759

Office sharing cost (AUD K)

1,0291,614

Consultancy fees (AUD K)

251942

Other expenses (AUD K, restated)

1,043898

Finance costs (AUD K)

65158

Depreciation (AUD K)

3526

Share-based payments (AUD K, within employee costs)

24358

Bonuses (AUD K, within employee costs)

4870

Balance Sheet

MetricFY2018FY2019FY2020

Total assets (AUD K)

—3,6953,635

Cash and equivalents (AUD K)

513253227

Trade and other receivables (AUD K)

—2,1152,373

of which related-party receivables gross (AUD K)

—2,2242,477

Total current assets (AUD K)

—2,6752,606

Total current liabilities (AUD K)

—2,8033,566

Short-term debt (AUD K)

—00

Long-term debt (AUD K)

—0970

Total debt (AUD K)

—0970

Net debt (AUD K; negative = net cash)

—-253742

Goodwill and intangibles (AUD K)

—301308

Investments in associates (AUD K)

—441581

Working capital (AUD K)

—-129-960

Total equity (AUD K)

1,900892-988

Accumulated losses (AUD K)

-4,930-6,028-8,241

Contributed equity (AUD K)

7,1847,1847,184

Cash Flow

MetricFY2019FY2020

Receipts from customers (AUD K)

6,2897,211

Payments to suppliers and employees (AUD K)

-6,404-8,154

Operating cash flow (AUD K)

-176-862

Capex: PP&E payments (AUD K)

0-18

Free cash flow (AUD K)

-176-880

Investment in associates (AUD K)

-83-75

Proceeds from borrowings (AUD K)

0927

Dividends paid (AUD K)

00

Share buybacks (AUD K)

00

Net change in cash (AUD K)

-259-28

Financial Analysis

ItemValueSourceVerification status

Results release date

27 Aug 2021

Investing.com

—

Revenue

329.04K (currency/period unclear)

Investing.com

It would imply a 95% revenue collapse from FY2020

EPS

−0.03 (AUD)

Investing.com

Would imply a loss of about A$3m on about 104m shares

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2019FY2020

ROE (%; average equity)

-78.7—

ROA (%; average total assets where available)

-29.7-60.4

Current ratio (x)

0.950.73

Debt to equity (x)

0.00—

Interest coverage, EBIT / interest expense (x)

-18.8-14.3

Asset turnover (x)

1.671.88

Days sales outstanding (days)

125126

Revenue by Region

RegionFY2019FY2020

Australia revenue (AUD K)

6,1616,900

United States revenue (AUD K)

00

Rest of world revenue (AUD K)

00

Revenue by Region by Segment × Region

Segment × regionFY2019FY2020

Consulting services, Australia (AUD K)

5,6486,760

Shared services, Australia (AUD K)

513140

Share Price and Market Valuation

MetricFY2016FY2017FY2018FY2019FY2020

Share price at 30 June (AUD)

0.250.250.250.290.13

Implied market cap at 30 June (AUD Mn, 103.925m shares)

26.026.026.030.113.5

Performance Measure Details

Performance measureValue

IPO price (May 2015)

A$0.30

Last quoted price

A$0.12 (prior close A$0.125); thinly traded (3-month average volume about 5.8k shares) — Investing.com historical page

Return IPO → FY2020 close

−56.7%

Return IPO → last quote

−60.0%

1-year / 3-year / 5-year return to Oct 2026

Not applicable (delisted Aug 2022). Realisable equity value likely nil given the administrators' creditor outlook

Relative performance (Market Index, vs ASX 200, 1 year, historical)

−23.58%

Valuation Multiples

MultipleiQ3Corp (FY2020 basis, at A$0.13)Comment

P/E

Not meaningful (loss)

—

EV/EBITDA

Not meaningful (negative EBITDA)

EV ≈ A$13.5m + A$0.74m net debt ≈ A$14.3m

EV/Sales

2.1x

Historical only

P/B

Not meaningful (negative book value)

—

Capital Markets

ItemStatus

Analyst coverage / consensus

None. MarketBeat shows no price target or consensus rating

Dividend history

None paid, declared or recommended in FY2016–FY2020

Buyback authorisations

None ("There is no current on-market share buy-back", FY2020 AR Note 20)

Capital raisings after IPO

None (contributed equity unchanged at A$7,184,247 in FY2018–FY2020)

Credit ratings (Moody's/S&P/Fitch)

Not rated

Debt maturity profile (30 Jun 2020)

A$42,559 accrued interest within 1 year; A$927,000 bond principal due 30 Jun 2022 (1–2 years); nothing beyond

Unrecognised tax losses

Deferred tax assets not recognised: A$4,003,325 (FY2020) vs A$2,140,438 (FY2019)

Performance rights outstanding

1,815,000 under the Employee Benefits Plan (at report date, Aug 2020)

Analyst Conclusions

Management guidance

The last management outlook (FY2020 Annual Report, August 2020) expected US contracts to produce a pipeline over 12–24 months and the full benefit of cost savings in FY2021. No quantitative guidance was ever issued. No management guidance applies today, because control rests with the external administrators.

Consensus

None exists. No analyst coverage was identified at any point.

Bull case (historical, with what has since happened)

  1. Captive pipeline: related-party mandates delivered A$6.8m of advisory fees in FY2020 (+19.7%). If group companies had kept raising capital, iQ3Corp would have kept earning fees. What happened: the group failed in March 2022.

  2. Cost flexibility: a Q4 FY2020 operating cash surplus of A$203k showed a path to cash breakeven. insolvency followed.

  3. Hidden associate value: the 40.5% OncoTEX stake was material enough for a confidential court valuation, giving potential recovery value. What happened: the result of any realisation is not publicly disclosed.

Bear case (all substantiated)

  1. Circular economics: 100% related-party revenue, A$1.6m of related-party office charges and related-party debt meant reported profitability was a matter of intragroup pricing.

  2. Balance sheet failure: negative equity (−A$0.99m), net current liabilities (−A$0.96m) and receivables owed by entities that later became insolvent.

  3. Governance: an insider-only board from March 2020, administrators' findings on intercompany loans and spending, and an ASIC referral.

Catalysts and monitorables for the next 12 months

MonitorableWhy it mattersWhere to check
Final outcome of the administration (DOCA vs liquidation) and any dividend to creditorsDetermines whether any residual value exists for stakeholdersASIC published notices; administrators' creditor portal
ASIC action on directors following the administrators' reportPotential disqualification or civil penalty proceedingsASIC media releases; Federal Court listings
Disrupt Group litigation outcomeAbout A$214m claim against group entitiesCourt records
Realisation of OncoTEX and New Frontier interestsPossible creditor recoveriesLiquidator/administrator reports
Deregistration of iQ3Corp Ltd (ACN 160 238 282)Final legal end of the entityASIC Connect company register

Analyst verdict

iQ3Corp Ltd is no longer an investable security. It was removed from the ASX Official List on 26 August 2022 and has been in external administration since March 2022, and its administrators told creditors that unsecured creditors of the group entities were unlikely to receive anything in a liquidation. On that evidence, holders of its 103.9 million ordinary shares should assume their equity is worthless unless the administration outcome shows otherwise.

On paper, iQ3Corp met the profile of a promising niche advisory boutique. It had an oversubscribed IPO, revenue that more than tripled in four years, a credentialed founder and a clear sector specialisation. The filings, however, contained every warning an analyst needed well before the collapse. Every dollar of FY2020 revenue came from related parties, and related-party receivables made up two-thirds of total assets. Office costs and debt funding came from the same group of companies. The company never raised equity after its IPO, yet accumulated losses rose from A$4.9m to A$8.2m in two years. The auditor flagged going concern, related party transactions and intangibles as key audit matters. In March 2020 the board removed its last independent directors and installed the Group CEO as Executive Chair, chairing both the audit and remuneration committees, while raising his fixed pay by 25% in a record-loss year.

The administrators' later findings were the natural consequence of these disclosures. They found mutually dependent group entities, unexplained intercompany write-offs, cross-entity payroll and questioned spending.

For risk professionals, the takeaway is that a single disclosure line ("revenue is derived only from related parties") combined with a negative-equity balance sheet should override any growth narrative. Investors should not view iQ3Corp as a turnaround candidate. The key open items are now forensic: the administration's final outcome, any ASIC action, and the Disrupt litigation.


APPENDIX — SOURCES

1: iQ3Corp Limited, 2020 Annual Report (year ended 30 Jun 2020), lodged 23 Oct 2020 — https://www.aspecthuntley.com.au/asxdata/20201023/pdf/02298344.pdf — Financials FY2016–FY2020, segments, governance, remuneration, entities

2: iQ3Corp Ltd, Appendix 4E and 2019 Annual Report (30 Aug 2019) — https://announcements.asx.com.au/asxpdf/20190830/pdf/4482njwl9nqmlw.pdf — FY2019 results; positioning

3: Robinson, in the matter of Farmaforce Limited (Administrators Appointed) [2022] FCA 397 (6 Apr 2022) — https://au.vlex.com/vid/robinson-in-the-matter-926800848 — Administration, listing dates, group structure findings

4: ASX Market Announcement, Removal from Official List – Annual Listing Fees (29 Aug 2022) — https://announcements.asx.com.au/asxpdf/20220829/pdf/45df4lf4w3tdxr.pdf — Delisting

5: ASX Market Announcement, Suspension from Official Quotation (22 Aug 2022) — https://announcements.asx.com.au/asxpdf/20220822/pdf/45d3db31lnq39s.pdf — Suspension status

6: FNN, "IQ3Corp Prospectus Offer Closes Oversubscribed" (11 May 2015) — https://www.finnewsnetwork.com.au/companyreports/iq3corp/20150511/iq3corp-prospectus-offer-closes-oversubscribed — IPO terms

7: Market Index, IQ3 profile — https://www.marketindex.com.au/asx/iq3 — Shareholders, auditor, relative performance

8: Investing.com, iQ3Corp Ltd historical data — https://uk.investing.com/equities/iq3corp-ltd — Last price; FY2021 aggregator data

9: MarketBeat, ASX:IQ3 profile — https://www.marketbeat.com/stocks/ASX/IQ3 — Service lines, incorporation year

10: MarketScreener insider profiles (Kosmas Dimitriou; George Syrmalis) — Officer changes; biography

11: CB Insights, iQ Group Global page (summarising July 2022 media coverage of the administrators' report) — https://www.cbinsights.com/company/iq-group-global — Creditor claims, ASIC referral, Disrupt claim, spending findings

12: NSX announcement registers for IQG and IQX — https://www.nsx.com.au/marketdata/company-directory/announcements/IQG/ — Group administration and delisting dates

13: Wikipedia, "IQnovate" — https://en.wikipedia.org/wiki/IQnovate — Group background; AFR citation (11 Mar 2022)

14: IQX Limited FY2013 financial statements (NSX) — https://www.nsx.com.au/ftp/news/021728022.PDF — iQX establishment; early group history

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameTitleTenurePrior rolesEducationHoldings (30 Jun 2020)

Dr George Syrmalis

Executive Chair, Executive Director and Group CEO

Group CEO throughout FY2020; Chair/Director from 20 Mar 2020

Founder, CEO and Chair, Bionuclear Group SA (1995–2005). Chair/ED of The iQ Group Global and iQX; ED of Farmaforce. Per MarketScreener: formerly Chairman of Intelligent Bio Solutions Inc., Medical Director at UCB Biopharma, Head of Medical Affairs at Sanofi-Aventis France

M.D., PhD; trained in nuclear medicine–radiation immunology

20,495,112 shares (~19.7%); 765,000 performance rights

Monika Pawel

Non-Executive Director

From 27 Aug 2019

Chief of Staff, The iQ Group Global. Previously R&D, sales and medical marketing at Roche and IQVIA; managed teams in Japan, Germany and the UK at CSL

BSc (Hons) Monash; MSc Medical Science UNSW; MBA Melbourne; MSc Major Programme Management, Oxford

Nil

Lei Xu

Executive Director

ED from 20 Mar 2020; joined iQ3Corp in 2014

Director APAC; Director, Structured Investment Products (iQ3Corp)

BSc Accounting, Jiangsu; MSc Management, Stirling; Executive MBA, AGSM; FCCA; China Certified Tax Agent

20,000 shares; 260,000 performance rights

Gerardo Incollingo

Company Secretary (FY2020)

—

Managing Director, LCI Partners; company secretary of Farmaforce, iQX and iQ Group Global

BCom (Wollongong); CPA

—

Kosmas Dimitriou

Company Secretary (from Jan 2022, per MarketScreener)

2,022

Former NED (2013–20 Mar 2020); Chairman of iQX; tax lawyer

BCom/LLB (Western Sydney); Dip Legal Practice (Tax), Sydney

—

“—” = not publicly disclosed.

Board of Directors — Peter Coolentianos

NameRoleDepartureBackground

Peter Coolentianos

Independent NED and Chair; chaired Audit & Risk and Remuneration & Nomination Committees

Resigned 20 Mar 2020

35 years in accounting; 22 years as partner at Economos Chartered Accountants; CPA

Kosmas Dimitriou

Independent NED

Resigned 20 Mar 2020

Tax lawyer, 18+ years; adviser to government and ATO on tax policy

Jimena Hurtado

NED

Resigned 27 Aug 2019

19+ years in pharma/medtech; former GM of Clinical Research Corporation

Directors' Remuneration

NameCash salary/feesBonusOtherSuperLong service leaveEquityTotal

Dr George Syrmalis

499,234071,57347,42748,77618,360685,370

Lei Xu (from 20 Mar 2020)

70,611017,1996,70822,4786,000122,996

Monika Pawel (from 27 Aug 2019)

31,004002,9450033,949

Peter Coolentianos (to 20 Mar 2020)

30,822002,9280033,750

Kosmas Dimitriou (to 20 Mar 2020)

27,398002,6030030,001

Jimena Hurtado (to 27 Aug 2019)

0000000

Total KMP

659,069

0

88,772

62,611

71,254

24,360

906,066

KMP remuneration

FY2019

FY2020

—————

Total KMP remuneration (AUD K)

804906—————

CEO total remuneration (AUD K)

679685—————

CEO pay as % of group revenue (%)

11.09.9—————

KMP pay as % of group revenue (%)

13.113.1—————

Directors' Remuneration (Annual)

Governance attributeStatus after 20 Mar 2020Assessment

Board size

3

Minimal

Independent directors

0 of 3. Pawel was a non-executive but was Chief of Staff at related party iQ Group Global; Syrmalis and Xu were executives

Departure from ASX Corporate Governance Principles Recommendation 2.4 (majority independent)

Chair/CEO separation

No. Syrmalis was both Executive Chair and Group CEO

Departure from Recommendation 2.5

Audit & Risk Committee

Chaired by Syrmalis; members Pawel and Xu

Executive-chaired audit committee; no independent members

Remuneration & Nomination Committee

Chaired by Syrmalis; members Pawel and Xu

CEO chairing the committee that sets his own pay

Board meetings FY2020

Pawel 6/6; Dimitriou and Coolentianos 5/5; Syrmalis and Xu 1/1 (post-appointment)

—

Remuneration consultants

None engaged in FY2020

—

Corporate governance statement

Claims "substantial" compliance with ASX Principles (3rd ed.) "to the extent appropriate"

Board structure suggests material exceptions

Major Shareholders

RankHolderShares%
1

Bioworx Capital Pty Ltd

17,905,00017.16
2

Derivative Investments Pty Ltd

14,061,11213.48
3

Biodynamic Investments Pty Ltd

8,888,8888.52
4

Zeolite Holdings Pty Ltd (Zeolite Discretionary A/C)

8,800,0008.43
5

Babi Holdings Pty Ltd (CLT Super Fund)

4,000,0003.83
6

Champ Power Holdings Ltd

3,500,0003.35
7

BG Ventures Ltd

3,250,0003.11
8

Biofarma Investments Pty Ltd (Biofarma A/C)

1,750,0001.68
9

Odams Pty Ltd (The Rangoon A/C)

1,716,6661.65
10

Oceana Horizon Pty Ltd (Oceana Horizon Invest Super)

1,000,0000.96

Competitive Landscape

Key Competitors

#CompetitorTypeRelevanceComparative revenue
1

Bell Potter Securities (Bell Financial Group, ASX: BFG)

Full-service broker

Leading small/mid-cap healthcare ECM in Australia

—
2

Canaccord Genuity (Australia)

Global mid-market investment bank

Active life science ECM

—
3

Morgans Financial

Broker/adviser

Healthcare IPOs and placements

—
4

Wilsons Advisory

Broker/advisory

Healthcare research and ECM

—
5

Taylor Collison

Boutique broker

Small-cap biotech placements

Private

6

Evolution Capital

Boutique

Small-cap biotech/healthcare raisings

Private

7

Henslow

Corporate advisory boutique

Life science M&A and capital

Private

8

Ord Minnett

Broker

Healthcare ECM

Private

9

Euroz Hartleys (Euroz Hartleys Group)

Broker

Small-cap ECM

—
10

MST Financial

Research/ECM boutique

Small-cap ECM

—
11

Petra Capital

Boutique

Small-cap ECM

Private

12

US small-cap banks (e.g., Maxim Group, ThinkEquity)

US investment banks

US microcap healthcare IPOs

—

Peer Comparison FY2020

MetriciQ3Corp FY2020Peer data

Revenue (AUD Mn)

6.9—

Revenue growth (%)

12.0—

EBITDA margin (%)

-29.4—

R&D intensity (%)

0

Not applicable to brokers

Share of revenue from related parties (%)

100

Typically minimal for peers (qualitative)

Recent Developments

Note on window: * There have been no company-originated disclosures since early 2022. That is well outside the 18 months before October 2026, which saw no reported developments.

Company Snapshot

$4.7M

Revenue

2012

Founded

Sydney, Australia

Headquarters

SWOT Analysis

Strengths

  • Sector specialisation: positioned as a dedicated life science corporate finance firm ("world's first", FY2019 AR) with a scientifically trained CEO (M.D., PhD, nuclear medicine).
  • Revenue scale-up after the IPO: revenue rose from A$2.12m (FY2016) to A$6.90m (FY2020), a 34.4% CAGR.
  • Successful IPO: A$4.4m raised at A$0.30, heavily oversubscribed, closing 1 May 2015.
  • Mostly variable cost structure: employee benefits fell from A$2.87m to A$1.76m in FY2020, showing costs could be cut quickly.
  • US platform: four US subsidiaries, including iQ Capital (USA) LLC, provided a legal foothold for US activity.
  • Associate interests: 40.5% of OncoTEX and 40% of New Frontier Holdings, with OncoTEX's value significant enough for a confidential court valuation in April 2022.

Weaknesses

  • Total related-party dependence: 100% of FY2020 revenue came from related parties (Note 4).
  • Negative equity: net liabilities of A$988,284 at 30 June 2020.
  • Going-concern material uncertainty: flagged in the FY2020 accounts and as a key audit matter.
  • Cash burn: operating cash outflow of A$861,536 in FY2020, five times FY2019's A$176,097.
  • Weak governance: no independent directors after 20 March 2020; Executive Chair also CEO; CEO chaired the audit and remuneration committees.
  • Receivables quality: related-party receivables of A$2.48m were 68% of total assets and about 126 days of revenue.

Opportunities

  • US investment banking: management cited signed US contracts and a 12–24 month pipeline (FY2020).
  • IP licensing and acquisition advisory: management expected more advisory work from life science asset licensing (FY2020 Chair's Report).
  • COVID-era diagnostics demand: related-party saliva biosensor programmes could have created capital-raising mandates.
  • Undrawn A$3m facility: liquidity headroom at 30 June 2020.
  • Going-concern sale under administration: the Court found an extension made a going-concern sale or restructure more likely ([2022] FCA 397).
  • Associate monetisation: potential realisation of the OncoTEX stake by the administrators.

Threats

  • Contagion from group insolvency: all four group companies entered administration in March 2022.
  • Large creditor claims: over A$60m claimed across group entities; about A$38m against iQ Group Global alone.
  • Litigation: Disrupt Group asserted a claim of about A$214m against group entities.
  • Regulatory action: administrators reported potential director-duty breaches to ASIC.
  • Loss of listing: removed from the ASX on 26 August 2022.
  • Lender failure: the funder (iQX) itself entered administration, cutting off the A$3m facility.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
28 Aug 2020FY2020 accounts signed; going-concern material uncertainty FY2020 ARFormal solvency warning
28 Aug 2020Revenue +12% to A$6.90m; loss doubles to A$2.21m FY2020 ARGrowth without profitability
28 Aug 2020Net liabilities of A$0.99m disclosed FY2020 AREquity wiped out
23 Oct 20202020 Annual Report lodged with ASX ASX cover letterLast audited report retrieved
FY2021 (dates n/d)Quarterly/half-year reporting —–
30 Jul 2021Substantial holder positions recorded (Bioworx, Derivative Investments, Biodynamic, Zeolite) Market IndexRegister concentration
27 Aug 2021FY2021 results released (aggregator) Investing.com–
Jan 2022Kosmas Dimitriou appointed company secretary MarketScreenerChange of officer
10–11 Mar 2022iQ Group Global announces voluntary administration "to restructure" NSX IQG register; MarketScreenerMain client and related-party debtor fails
Mar 2022iQ3Corp, Farmaforce and iQX enter administration alongside iQ Group Global [2022] FCA 397; media reportsCompany enters insolvency
11 Mar 2022AFR reports the biotech group's fall "from sponsoring race cars to administration" AFR (via Wikipedia citation)Reputational event
18 Mar 2022First affidavit of administrator Mark Robinson sworn [2022] FCA 397Court process begins
6 Apr 2022Federal Court extends convening period to 5 Jul 2022 [2022] FCA 397More time for a sale or restructure
6 Apr 2022Court notes complex structure, unexplained intercompany loan write-offs and cross-entity payroll [2022] FCA 397Governance findings on the record
6 Apr 2022OncoTEX Inc valuation placed under a confidentiality order [2022] FCA 397Associate value contested or sensitive
Jul 2022Administrators' report: creditors claim more than A$60m across group entities Media reporting (via CB Insights)Scale of the collapse
Jul 2022Administrators report potential breaches of directors' duties to ASIC Media reportingRegulatory exposure
Jul 2022Administrators question director-linked spending, including dinners, donations to an orphanage and a group-owned yacht ("Thalatta") Media reportingGovernance and conduct concerns
Jul 2022Disrupt Group gives notice of a claim of about A$214m against iQ Group entities (alleged misuse of commercialisation plans for a saliva test device) Media reportingLarge contingent claim
Jul 2022Administrators indicate unsecured creditors unlikely to receive any return in a liquidation Media reportingEquity worthless in practice
22 Aug 2022ASX confirms IQ3 already suspended and has not paid FY2023 listing fee ASX announcementPre-delisting notice
26 Aug 2022Removed from ASX Official List (Listing Rule 17.15) ASX announcement, 29 Aug 2022End of listed status
19 Sep 2022iQX and iQ Group Global delisted from NSX NSX registersWhole group delisted
After Sep 2022Outcome of the second creditors' meeting (DOCA or liquidation) —Not publicly disclosed in sources retrieved

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

4 charts
Income Statement: Revenue & Gross Profit: Cost of sales rose from AUD 1.9 Mn in FY2019 to AUD 4 Mn in FY2020.
iQ3Corp Ltd — Income Statement: Revenue & Gross Profit
Series (AUD Mn)FY2019FY2020
Cost of sales1.94

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.